Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6 , a New Urothelial Cancer Biomarker

4 Mar 2016

Abstract excerpt

SLITRK6 is a member of the SLITRK family of neuronal transmembrane proteins that was discovered as a bladder tumor antigen using suppressive subtractive hybridization. Extensive immunohistochemistry showed SLITRK6 to be expressed in multiple epithelial tumors, including bladder, lung, and breast cancer as well as in glioblastoma. To explore the possibility of using SLITRK6 as a target for an antibody-drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 14-3-3 protein interactions
Share to Colorectal Cancer Treatments and Studies
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26944921
DOI: 10.1158/1535-7163.mct-15-0570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Development of ASG-15ME, a Novel Antibody–Drug Conjugate Targeting SLITRK6 , a New Urothelial Cancer BiomarkerPMID 26944921Read ↗

Siglec-15 as an Emerging Target for Next-generation Cancer ImmunotherapySemantic proximity Read ↗

Targeting the ITGA3B1 Complex with A Novel Antibody-Drug Conjugate for Metastatic Bladder CancerSemantic proximity Read ↗

Targeting LAMP2 synergizes with gemcitabine to inhibit bladder cancer progression via modulating STING degradation and regulating macrophage phenotypes.Semantic proximity Read ↗

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancerSemantic proximity Read ↗

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read ↗

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificitySemantic proximity Read ↗

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in VivoSemantic proximity Read ↗

Molecular structure, expression, and the emerging role of Siglec‐15 in skeletal biology and cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.